Atlas Trials

KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

Clinical trial NCT03342937 · COMPLETED

Trial details

NCT number
NCT03342937
Sponsor
Duke University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric CancerEsophagus Cancer
Start date
2018-01-11
Primary completion
2023-02-06
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.